


## ARN2966

|                           |  |       |         |
|---------------------------|--|-------|---------|
| <b>Cat. No.:</b>          | HY-18292   |       |         |
| <b>CAS No.:</b>           | 102212-26-0                                      |       |         |
| <b>Molecular Formula:</b> | C <sub>12</sub> H <sub>12</sub> N <sub>2</sub> O |       |         |
| <b>Molecular Weight:</b>  | 200.24   |       |         |
| <b>Target:</b>            | Amyloid- $\beta$                                 |       |         |
| <b>Pathway:</b>           | Neuronal Signaling                               |       |         |
| <b>Storage:</b>           | Powder   | -20°C | 3 years |
|                           |  | 4°C   | 2 years |
|                           | In solvent                                       | -80°C | 2 years |
|                           |  | -20°C | 1 year  |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 110 mg/mL (549.34 mM; Need ultrasonic)

| Concentration             | Solvent | Mass      |            |            |
|---------------------------|---------|-----------|------------|------------|
|                           |         | 1 mg      | 5 mg       | 10 mg      |
| Preparing Stock Solutions | 1 mM    | 4.9940 mL | 24.9700 mL | 49.9401 mL |
|                           | 5 mM    | 0.9988 mL | 4.9940 mL  | 9.9880 mL  |
|                           | 10 mM   | 0.4994 mL | 2.4970 mL  | 4.9940 mL  |

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility:  $\geq$  2.75 mg/mL (13.73 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline)  
Solubility:  $\geq$  2.75 mg/mL (13.73 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of A $\beta$ . IC50 value: Target: A $\beta$  This potent post-transcriptional modulation of APP expression differs from other mechanisms such as inhibition of secretases. Secretase inhibitors have been pursued as disease modifying strategies by a number of pharmaceutical firms but they have encountered numerous setbacks during clinical development. ARN2966 is non toxic, orally absorbable, blood-brain-barrier penetrable, and effective in vitro and in vivo.

### REFERENCES

---

[1]. yodeji Asuni, et al. An APP translation modulator ARN2966 reduces BETA-AMYLOID deposition and prevents memory deficits in ALZHEIMER'S DISEASE transgenic mice. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2012.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA